![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » RedHill Biopharma Starts Global Trial of Yeliva for COVID-19
RedHill Biopharma Starts Global Trial of Yeliva for COVID-19
![RedHillBiopharma_Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/RedHillBiopharma_Logo.png?t=1596147791&width=430)
Redhill Biopharma has launched a global phase 2/3 trial of its Yeliva (opaganib) for treatment of hospitalized COVID-19 patients with pneumonia requiring supplemental oxygen.
The trial will enroll 270 patients to find the proportion of patients requiring intubation and mechanical ventilation by day 14.
Participants will receive Yeliva or a placebo along with the standard-of-care.
Upcoming Events
-
21Oct